Which patient groups have been included in sapropterin (BH4) studies?
Sapropterin studies have included specific patient populations defined by the underlying form of hyperphenylalaninemia, most often:
- People with phenylketonuria (PKU), including both children and adults, where sapropterin is tested for its ability to lower blood phenylalanine.
- People with “tetrahydrobiopterin (BH4)–responsive” hyperphenylalaninemia (a subgroup identified by prior testing or enrollment criteria based on responsiveness).
What “specific populations” does the literature commonly distinguish within PKU?
Across clinical studies, PKU participants are commonly categorized by factors such as:
- Age group (pediatric vs adult cohorts).
- Baseline severity and pretreatment phenylalanine levels (used to define eligibility and measure response).
- Documented BH4 responsiveness (some trials focus on responders or identify responders during screening).
Do sapropterin studies include special subgroups (e.g., pregnancy or severe disease)?
Some clinical programs and studies also focus on groups with additional clinical considerations, such as:
- Pregnancy-related use (reported in literature for preventing/controlling maternal phenylalanine levels when applicable).
- Participants with neurologic or developmental outcomes being tracked over time in pediatric cohorts.
What populations are most likely to match typical “sapropterin responder” study wording?
If you are looking for the language used to describe groups in trial papers, search terms usually map to:
- “BH4-responsive hyperphenylalaninemia”
- “PKU” (sometimes with “treated” or “untreated” depending on design)
- “screening test responders” (people identified as responsive through a phenylalanine reduction test)
I can be more precise if you share the study/citation you mean
Your question asks for “specific populations in sapropterin studies,” but different trials include different eligibility criteria. If you tell me which study (author name, year, or trial registration number like NCT/ClinicalTrials.gov), I can list the exact populations and inclusion criteria used in that paper (for example, age ranges, responsiveness definition, and diagnostic categories).
Sources cited
No sources were provided in your prompt, so I can’t name specific populations from particular study reports yet.